Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals Inc (IONS) Options Open Interest
IONS options open interest is 79,408 contracts. The 2-week average daily volume is 2,601 contracts across the chain.
Read more
Monitoring IONS open interest helps you see where real money is positioned on Ionis Pharmaceuticals Inc's options and which strikes are attracting the most commitment from traders. Ionis Pharmaceuticals Inc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor IONS options open interest in real time and find the strikes that matter.
Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising IONS options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect Ionis Pharmaceuticals Inc to settle.
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1.
In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where IONS open interest is concentrated. Our scanner maps Ionis Pharmaceuticals Inc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade Ionis Pharmaceuticals Inc's options open interest as the signal it is, not as an afterthought.
| 60.00 | — | 0.25 | 0.25 | 70% | +0.0715 | 2,449 |
| 57.50 | — | 1.00 | 1.00 | 91% | +0.1848 | 1,687 |
| 70.00 | — | 0.75 | 0.75 | 122% | +0.1180 | 1,602 |
| 80.00 | — | 0.65 | 0.65 | 142% | +0.0939 | 1,582 |
| 55.00 | 0.10 | 0.30 | 0.20 | 51% | +0.0758 | 1,435 |
| 52.50 | 6.90 | 8.80 | 7.85 | 6% | -1.0000 | 3,325 |
| 40.00 | 0.65 | 0.75 | 0.70 | 50% | -0.1948 | 3,086 |
| 60.00 | 13.50 | 16.60 | 15.05 | 10% | -1.0000 | 1,601 |
| 57.50 | 11.00 | 13.60 | 12.30 | 8% | -1.0000 | 1,111 |
| 50.00 | 5.00 | 6.90 | 5.95 | 45% | -0.8100 | 888 |
As of September 18, 2026
Follow the money
Track IONS open interest across every strike and expiration, identify where conviction is building, and trade with the positioning data on your side.
Start your 14-day free trial→